Clinical Trial Results:
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Evaluating the Efficacy and Safety of IPI-504 in Patients with Metastatic and/or Unresectable Gastrointestinal Stromal Tumors Following Failure of at Least Imatinib and Sunitinib
Estudio en fase 3, multicéntrico, aleatorio, doble-ciego y controlado con placebo para evaluar la eficacia y seguridad de IPI-504 en pacientes con tumores metastásicos y/o irresecables del estroma gastrointestinal después del fracaso de al menos Imatinib y Sunitinib
Summary
|
|
EudraCT number |
2008-002396-28 |
Trial protocol |
DE CZ ES SE DK NL IT BE FR GB |
Global completion date |
15 Apr 2009
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
29 Apr 2016
|
First version publication date |
29 Apr 2016
|
Other versions |
|
Summary report(s) |
IPI-504-06 CSR |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.